Oncoinvent - Q3 presentasjon

AksjeInvest
ONCOIN 23.10.2020 kl 11:33 368

Clinical
experience so far

9 patients successfully treated

No adverse events related to Radspherin treatment have
been reported to date

Imaging data from all 9 patients indicates that the
administration of Radspherin has been successful and that
administration procedures and equipment work as intended


https://www.oncoinvent.com/wp-content/uploads/Q3-2020-report-presentation.pdf
Redigert 20.01.2021 kl 13:01 Du må logge inn for å svare